Ganglion cells help set the human body clock

Article

Cells at the back of the eyes of profoundly blind people monitor light levels and use them to set the body's clock to either day or night.

Cells at the back of the eyes of profoundly blind people monitor light levels and use them to set the body's clock to either day or night, according to a report published in the December issue of Current Biology.

Russell Foster from the Nuffield Laboratory of Ophthalmology, University of Oxford, UK and colleagues from other UK and US centres conducted an experiment on two blind people who lack the rods and cones needed for normal vision.

For 6.5 hours, the researchers shone light into the eyes of a 56-year old blind man and an 87-year old blind woman. When they used the blue light at night-time, they were able to delay the body clock cycle by 1.2 hours, proving that the ganglion cells were registering light. At the same time, blood levels of the sleep hormone melatonin fell by 60% and the patients' alertness sharpened and brain activity increased, demonstrating that the body clocks had been "fooled" into thinking it was daytime.

The researchers believe that the results of this study explain why blind people, who have had their eyes removed for cosmetic or health reasons, can suffer significant sleep disruption.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.